Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability

2026-09269 · notice · published 2026-05-11

Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Pulmonary Tuberculosis: Developing Drugs for Treatment." The purpose of this guidance is to assist sponsors in the clinical development of new antibacterial drugs for the treatment of pulmonary tuberculosis (TB). This guidance finalizes the draft guidance of the same title issued on December 15, 2022.

Agencies: Health and Human Services Department (HHS), Food and Drug Administration (FDA)
Dockets: Docket No. FDA-2013-D-1319

View at federalregister.gov → · PDF · XML

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.